Navigation Links
Neuralstem's NSI-189 trial in major depressive disorder receives FDA approval to advance to Phase Ib
Date:12/27/2011

has created virtually unlimited amounts of mature human neurons and glia in laboratory dishes. These can be used to mimic the natural brain environment in order to test drug effects.

Neuralstem has been engaged in its own drug discovery program with these human hippocampal stem cell lines since 2000. In 2009, Neuralstem was granted U.S. patents on four first-in-class chemical entities that boost the generation of new neurons. NSI-189, the first of these to be in a clinical trial, significantly stimulates the generation of new hippocampal neurons (neurogenesis) in vitro and in animal models, above and beyond the neural stem cells' innate differentiation.

NSI-189 is the lead compound in Neuralstem's neuroregenerative small molecule drug platform, which the company plans to develop into orally administered drugs for MDD and other psychiatric disorders, such as Alzheimer's disease, anxiety, bipolar disorder and post traumatic stress disorder.

NSI-189 stimulated neurogenesis of human hippocampus-derived neural stem cells in-vitro. In healthy normal adult mice, NSI-189 stimulated neurogenesis in the hippocampus and significantly increased its volume, apparently by increasing its synaptic network after 28 days of daily oral administration. In mouse models of depression, NSI-189 significantly improved behavioral responses associated with depression. In humans, NSI-189 may reverse the human hippocampal atrophy seen in MDD and other disorders and reverse their symptoms. This program has received significant support from both the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH).

About the Trial

The NSI-189/MDD trial is a randomized, double-blind, placebo-controlled, multiple-dose escalating trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamic effect of NSI-189 in the treatment of MDD. Phase Ia tested escalating doses of single administration of NSI-
'/>"/>

Contact: Deanne Eagle
deanneeagle@gmail.com
917-837-5866
Neuralstem, Inc.
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Women More Likely to Fail Treatment for Atrial Fibrillation
2. Single gene mutation induces endometrial cancer
3. NEJM Publishes Trial Results Demonstrating Bard FLAIR Endovascular Stent Graft Is Superior To Balloon Angioplasty For Failing Dialysis Grafts
4. MCG to conduct first FDA-approved stem cell trial in pediatric cerebral palsy
5. In Tests, Implanted Monitor Detects Atrial Fibrillation
6. Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials
7. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
8. Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinsons
9. WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday
10. WellPoint/Blue Cross Liver Transplant Denial Trial Begins Today, Illustrates Need for Toughening of White House Reform Plan
11. Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... The Mount Sinai Health System will work with ... potential of related, experimental treatments. The collaboration moves into the next phase with the ... one of five state licenses to produce and dispense medical marijuana. , Mount ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently, ZKB ... of Ohio, Western Division (Case No. 3:15-cv-00397) involving the Implanon® contraceptive implant ... spontaneous migration of their Implanon® implants, inability to locate the implants, unsuccessful and ...
(Date:7/31/2015)... ... July 31, 2015 , ... Florida ... novel catheter that was developed for targeted delivery of fluids to selected sites ... treated at Florida Hospital Tampa with the device that provides direct, local delivery ...
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 hair ... that they are the latest recipients of the Center of Clinical Excellence for ... the worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration ...
(Date:7/31/2015)... ... July 31, 2015 , ... Healthpointe ... a newly redesigned website at Healthpointe.net. The new website will feature a sleek ... The redesign serves to provide smoother interactions between patients and the Healthpointe clinics ...
Breaking Medicine News(10 mins):Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Healthpointe Announces Newly Redesigned Website 2
... ... been developed. Experienced weight loss physicians have raised the HCG diet caloric daily allowance from ... diet protocol written 50 years ago. The physician’s goal with this new HCG diet protocol ... patients. , ...
... ... place on May 6, 2010. Two years in the planning and development, the cutting-edge ... nonsurgical laser treatments for varicose veins and spider veins. , ... Prescott, AZ (PRWEB) April 27, 2010 -- Prescott Vein Specialties ...
... with chronic kidney disease have more severe anemia than white ... a multicenter study led by Johns Hopkins Children,s Center to ... Journal of Kidney Disease . The findings suggest that ... may be at play, raising the question whether current guidelines ...
... studies finds that patients, research participants and journal readers ... disclosed, in part because those financial ties may influence ... the April 26 issue of Archives of Internal ... ties to the pharmaceutical, biotechnology and medical device industries ...
... ─ Tiny, melanin-covered nanoparticles may protect bone marrow from ... at Albert Einstein College of Medicine of Yeshiva University ... these particles into human patients may hold promise in ... issue of the International Journal of Radiation Oncology, ...
... are most likely to be good candidates upon death, ... U.S. researchers have developed a new tool that may ... donors, a development that could potentially boost organ donation ... often good candidates for organ donation when they die ...
Cached Medicine News:Health News:Breakthrough in HCG Weight Loss Therapy 2Health News:Breakthrough in HCG Weight Loss Therapy 3Health News:New Varicose Vein Treatment Center Opens in Prescott, Arizona 2Health News:Anemia tougher to tackle in black children with kidney disease 2Health News:Patients, clinicians favor disclosure of financial ties to industry 2Health News:Patients, clinicians favor disclosure of financial ties to industry 3Health News:Novel nanoparticles prevent radiation damage 2Health News:Novel nanoparticles prevent radiation damage 3Health News:Novel nanoparticles prevent radiation damage 4Health News:Test Spots Potential Organ Donors Among Coma Patients 2
(Date:7/30/2015)... 2015 P&S Market ... market overview, trends, DRO analysis, market segmentation, ... developments, competitive scenario and top competitor profiles ... Market Development and Demand Forecast to 2020  ... Explore more about global biosensors ...
(Date:7/30/2015)... , July 30, 2015   Gaumard® Scientific ... to UNI®, the world,s first operating system to ... now available exclusively to Gaumard users. UNI® version ... launched Newborn Tory™ S2200, as well as improvements ... of clinical measures such as EtCO 2 .  ...
(Date:7/30/2015)... VIEJO, Calif. , July 30, 2015 /PRNewswire/ ... aspiring to eliminate all preventable hospitalization, recently received ... that its Remote Patient Intelligence (RPI) solution meets ... the FDA intends to exercise "Enforcement Discretion." ... "are not subject to further FDA regulatory requirements ...
Breaking Medicine Technology:Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 2FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 3
The RapidBARBITURATE test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of barbiturates and in human urine specimens above a cut-off level of 3...
... With membrane parasite ... and cytoplasm as antigen. ... different antigens than the ... possible to use two ...
Elisa test for qualitative detection of Total antibodies to Trypanosoma Cruzi in human serum or plasma....
Silicone ICD lead...
Medicine Products: